Menopausal Disorder Treatment Global Market Report 2025

The menopausal disorder treatment market size has grown strongly in recent years. It will grow from$10.69 billion in 2024 to $11.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to an aging female population, heightened awareness of menopause-related health concerns, a high prevalence of obesity which can worsen menopausal symptoms, increasing acceptance of hormone replacement therapy (HRT), and advancements in personalized medicine.

The menopausal disorder treatment market size is expected to see strong growth in the next few years. It will grow to$15.3 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth anticipated during the forecast period can be attributed to rising healthcare infrastructure spending, a stronger focus on women's health initiatives, increasing collaborations between pharmaceutical companies and research institutions, and growing urbanization leading to lifestyle changes that affect menopausal health. Key trends expected in this period include a shift toward natural and herbal treatment options, the integration of artificial intelligence in treatment planning, the emergence of wearable devices for real-time symptom tracking, an emphasis on holistic wellness programs addressing menopause, and increased investment in women's health startups developing menopause-related solutions.

The growing demand for hormone replacement therapies (HRT) is expected to drive the expansion of the menopausal disorder treatment market. HRT involves the medical process of supplementing or replacing hormones to alleviate the symptoms associated with menopause or hormonal imbalances. The rise in HRT usage is largely fueled by increasing awareness and demand for effective management of menopausal symptoms and hormonal imbalances. HRT addresses menopausal disorders by replenishing estrogen and progesterone levels, helping to restore hormonal balance and alleviate disruptive symptoms such as hot flashes, night sweats, and mood swings, thus improving the quality of life. For example, in October 2024, the NHS Business Services Authority (NHSBSA), a UK-based organization offering various support services, reported a 22% increase in HRT prescriptions, reaching 13 million items. Additionally, the number of patients identified for HRT rose by 12%, from 2.3 million in 2022/23 to 2.6 million in 2023/24. This growing demand for hormone replacement therapies is contributing to the growth of the menopausal disorder treatment market.

Leading companies in the menopausal disorder treatment market are developing advanced nonhormonal therapies, such as neurokinin 3 (NK3) receptor antagonist drugs, to effectively manage vasomotor symptoms without the use of hormones. These novel therapies work by blocking NK3 receptors to manage menopausal symptoms, providing an alternative to traditional hormone treatments. For instance, in December 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from the European Commission for Veozah (fezolinetant), a non-hormonal NK3 receptor antagonist aimed at treating moderate to severe vasomotor symptoms (VMS), including hot flashes and night sweats in menopausal women. Veozah operates by targeting neurons in the brain’s temperature regulation center, reducing the frequency and intensity of these symptoms.

In October 2022, Unified Women’s Healthcare, a US-based company specializing in comprehensive women’s health services, acquired Gennev for an undisclosed amount. This acquisition strengthens Unified Women’s Healthcare’s position in menopause care in the U.S. by expanding its digital health offerings and improving access to specialized care for women experiencing menopause. Gennev is a US-based digital health platform offering personalized and comprehensive menopause treatment services.

Major players in the menopausal disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Novo Nordisk A/S, Abbott Laboratories, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Ipsen SA, Dr. Reddy’s Laboratories Ltd., Theramex, Besins Healthcare, Mithra Pharmaceuticals, Duchesnay USA, Fervent Pharmaceuticals, Joylux Inc., and TherapeuticsMD Inc.

North America was the largest region in the menopausal disorder treatment market in 2024. The regions covered in menopausal disorder treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the menopausal disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Menopausal disorder treatment encompasses a variety of medical and therapeutic approaches designed to relieve symptoms associated with menopause such as hot flashes, mood fluctuations, sleep issues, and hormonal imbalances aiming to enhance the overall well-being and quality of life for individuals undergoing this transitional phase.

The primary types of menopausal disorder treatments include hormone replacement therapy (HRT), non-hormonal treatments, herbal supplements, and lifestyle changes. Hormone replacement therapy helps regulate hormone levels in women experiencing menopause-related symptoms such as hot flashes, mood swings, and reduced bone density. These treatments are relevant across various stages of the menopausal journey, including perimenopause, menopause, and postmenopause, and are used to address symptoms such as night sweats, mood changes, hot flashes, and vaginal dryness. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are utilized by various end users including hospitals, specialty clinics, home care environments, and more.

The menopausal disorder treatment market research report is one of a series of new reports that provides menopausal disorder treatment market statistics, including the menopausal disorder treatment industry's global market size, regional shares, competitors with a menopausal disorder treatment market share, detailed menopausal disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the menopausal disorder treatment industry. This menopausal disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menopausal disorder treatment market includes revenues earned by entities providing services such as estrogen-only therapy, combined estrogen and progesterone therapy, bone health management, and hormone level testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal disorder treatment market also includes sales of hormone replacement therapy (HRT) medications, non-hormonal therapies, dietary supplements, and vaginal estrogen products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.